TD Cowen Maintains Buy on Insmed, Raises Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Ritu Baral maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $45 to $67.
May 29, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Ritu Baral maintains a Buy rating on Insmed and raises the price target from $45 to $67.
The Buy rating and significant increase in price target from $45 to $67 by a reputable analyst is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100